ArticleBMJ open2019
Effect of the public disclosure of industry payments information on patients: results from a population-based natural experiment.
Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Distribution of industry-sponsored research payments to US physician principal investigators.PloS one · 2026Observational
- Practice-Level Clustering of Industry Payments to Clinicians.Health services research · 2025Article
- "I never thought of it as payment": Qualitative evaluation of workshops with advanced practice registered nurses on pharmaceutical industry payment reporting.Journal of the American Association of Nurse Practitioners · 2025Article
- From symbolism to substance: evaluating state disclosure laws and the case for federal oversight.Frontiers in health services · 2025Article
- Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States.Gynecologic oncology · 2024Article
- Assessing the impact of the Physician Payments Sunshine Act on pharmaceutical companies' payments to physicians.PloS one · 2024Article
- Increasing trends of pharmaceutical payments to breast cancer specialists in Japan: A retrospective study from 2016 to 2019.PloS one · 2024Article
- Article
- Article
- Geographic distribution of general industry payments to advanced-practice clinicians.Health affairs scholar · 2023Article
- International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency.Globalization and health · 2023Article
- Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019.International journal of environmental research and public health · 2022Article
- Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians.International journal of environmental research and public health · 2022Article
- Pharmaceutical Sales Representatives in the United States and China: The Need for Professional Public Space.Health care analysis : HCA : journal of health philosophy and policy · 2022Article
- Center Reputation and Experience Relate to Industry Payments to Congenital Heart Disease Providers.The Annals of thoracic surgery · 2021Article
- Orthopaedic Trauma Surgeons' Financial Relationships With Industry: An Analysis of the Sunshine Act Reporting of Physician Open Payments From 2014 to 2019.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2021Article
- Drug company payments to General Practices in England: Cross-sectional and social network analysis.PloS one · 2021Article
- Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation.Journal of bioethical inquiry · 2020Article
- US Nationwide Disclosure of Industry Payments and Public Trust in Physicians.JAMA network open · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the effect of the public disclosure of industry payments to physicians on patients' awareness of industry payments and knowledge about whether their physicians had accepted industry payments.
designInterrupted time series with comparison group (difference-in-difference analyses of longitudinal survey).
settingNationally representative US population-based surveys. Surveys were conducted in September 2014, shortly prior to the public release of Open Payments information, and again in September 2016.
participantsAdults aged 18 and older (n=2180).
main outcome measuresAwareness of industry payments as an issue; awareness that industry payments information was publicly available; knowledge of whether own physician had received industry payments.
resultsPublic disclosure of industry payments information through Open Payments did not significantly increase the proportion of respondents who knew whether their physician had received industry payments (p=0.918). It also did not change the proportion of respondents who became aware of the issue of industry payments (p=0.470) but did increase the proportion who knew that payments information was publicly available (9.6% points, p=0.011).
conclusionsTwo years after the public disclosure of industry payments information, Open Payments does not appear to have achieved its goal of increasing patient knowledge of whether their physicians have received money from pharmaceutical and medical device firms. Additional efforts will be required to improve the use and effectiveness of Open Payments for consumers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.